The retinal thickness factor: As my computer code shows, the retinal thickness factor R_th was considered for Holladay I and SRK-T (in different ways, of course) but not for Hoffer Q.
The question of checking with the formula author or the manufacturer: On recommendation of the Eye editorial board, the article was sent before publication to both the formula author and Carl Zeiss Meditech, and their valuable comments were taken into consideration in this article. So the comment about not validating the formula with the author(s) is premature, injudicious and deplorable.
It is best to reiterate here that IOLMaster's accuracy for biometry and HofferQ formula's predictive power have been established well. The point in question in the article, however, is whether the IOLMaster is as accurate in implementing the IOL formulas or if there is scope of any error. This paper is an attempt in that direction. To label this attempt as 'blatantly detrimental' is a gross injustice to any scientific criticism. Unfortunately, while the aforesaid main issue remains unsolved, the focus of discussion has digressed elsewhere.
It is painful to hear that one should use only an 'approved and licensed' version of a formula, and not the one that is published in the public domain. 2 We report a case of Fabry disease presenting with chronic uveitis, cystoid macular oedema, and marked visual impairment. It responded only temporarily to periocular steroid injections and was finally stabilized under enzyme replacement therapy (ERT). To our knowledge, these unusual manifestations and the treatment have never been reported.
Case report
A 22-year-old man visited us in May 2002 and complained of progressive decreased vision (OU) for 4 years, along with acroparesthesia, hypohidrosis, and heat intolerance. Best-corrected visual acuity (BCVA) was 20/400 (OD) and 20/200 (OS). Ophthalmological exams showed bilateral vortex keratopathy, anterior chamber reaction, anterior subcapsular cataract, vitreous haze, periarterial infiltrate, cystoid macular oedema (Figure 1a and b), and diffuse vascular leakage (Figure 1c and d) . Optical coherence tomography (OCT) showed severe macular oedema (Figure 1e and f) . Fabry disease was confirmed by enzymatic analysis. Investigations looking for other causes of uveitis were all negative.
Because the clinical condition progressed, a therapeutic trial with posterior subtenon steroid injection (triamcinolone acetonide 20 mg, OU) was performed. Two weeks later, BCVA improved to 20/70 (OD) and 20/100 (OS). The vitreous haze and macular oedema partially resolved (Figure 1g and h) . However, the inflammation waxed and waned despite subsequent periocular steroid injections. BCVA decreased to counting fingers at 40 cm (OU) owing to macular oedema, cataract, and severe vitreous haze. He received ERT (agalsidase alfa, 10.5 mg every 2 weeks from September 2002 to November 2003; agalsidase beta, 70 mg every 2 weeks since December 2003) and cataract extraction (OD, November 2002; OS, May 2003) . After 24 weeks of ERT, acroparesthesia, hypohidrosis, and heat intolerance relieved and the uveitis-like picture gradually subsided. Subsequently, he underwent pars plana vitrectomy (OD) for persistent severe vitreous opacity. Postoperatively, the macula showed mottling change without oedema (Figure 2a) . Although no inflammatory signs such as vitreous cells were noted in the left eye, severe vitreous opacity still obscured the fundus and probably affected the vision (Figure 2b) . The latest BCVA was 20/400 (OD) and 20/800 (OS).
Comment
The most common retinal manifestation of Fabry disease is large vessel tortuosity.
2 In contrast, this case presented with uveitis, vitreous haze, vascular leakage, cystoid 
